Boston Scientific Corporation
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Boston Scientific Corporation sits in the top decile of US sponsors by registered trial count (#122 of 15,742 sponsors by registered trial count).
Boston Scientific Corporation: 280 sponsored US clinical trials, 22 recruiting.
Boston Scientific Corporation sponsors 280 registered US clinical trials on ClinicalTrials.gov, 22 of them currently recruiting, and 207 completed. 59 of these trials are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Coronary Artery Disease, with 8 trials.
Top-decile sponsor footprint
Boston Scientific Corporation ranks in the top decile of sponsors by registered trial count (#122 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
207 of 239 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
280 total, page 2 of 6
CLBP Single-Arm Long-Term Follow-up Study
NCT05207813
Step and Walking Pattern From Cardiac Monitor Study
NCT04971993
Flexiva Pulse Registry
NCT05027971
SpyGlass™ Discover Percutaneous
NCT04580940
Study to Evaluate Automated Intensity Management in Patients Undergoing a BSC SCS Temporary Trial
NCT04909593
A U.S Post Approval Study Evaluating the SYNERGY XLV (MEGATRON) Stent System
NCT04807439
Clinical Evaluation of the StablePoint Catheter and Force Sensing System for Paroxysmal Atrial Fibrillation
NCT04580914
SCS as an Option for Chronic Low Back and/or Leg Pain Instead of Surgery
NCT04676022
Global Prospective Case Series Using a Single-Use Duodenoscope
NCT04103749
LUX-Dx Insertable Cardiac Monitor Remote Programming and Performance Study
NCT04732728
The FARAPULSE ADVENT PIVOTAL Trial PFA System vs SOC Ablation for Paroxysmal Atrial Fibrillation
NCT04612244
Radiofrequency (RF) Ablation Prospective Outcomes Study
NCT04673032
Postmarket Outcomes Study for Evaluation of the Superion™ Spacer
NCT04563793
INGEVITY+ Active Fixation Pace/Sense Lead Clinical Study
NCT04346537
Physiological Signals, Activity and Posture for Surface Mounted Insertable Cardiac Monitor in Heart Failure Study
NCT04112576
Boston Scientific's Cryoballoon in the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation
NCT04133168
Double-J PLUS Postmarket Registry Study
NCT04197583
PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement
NCT04149535
Initial Case Series With Exalt Single-Use Duodenoscope - Expanded User Experience
NCT04223830
Fast-Acting Subperception Study (FAST)
NCT04231409
Artificial Urinary Sphincter Clinical Outcomes
NCT04088331
Data Collection - Of Syncope Tilt Table Testing Study
NCT03721393
AXIOS™ for Gallbladder Drainage as an Alternative to Percutaneous Drainage IDE
NCT03767881
Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation
NCT03795298
A Clinical Trial to Confirm Safety & Effectiveness of the SYNERGY 4.50 mm and 5.00 mm Stent for Treatment of Atherosclerotic Lesion(s)
NCT03875651
Radiopaque Hydrogel Spacer in Patients Undergoing Radiotherapy for Pancreatic Cancer
NCT03998566
Initial Case Series With Exalt Single-Use Duodenoscope
NCT03701958
Cardiac Monitor Employee Study
NCT03826225
Prospective Evaluation of Open Irrigated Ablation Catheters With High Resolution Mapping to Treat Paroxysmal Atrial Fibrillation
NCT03729830
REPRISE IV: LOTUS Edge Valve System in Intermediate Surgical Risk Subjects
NCT03618095
Cholangioscopy in Primary Sclerosing Cholangitis (PSC)
NCT03766035
Combining Mechanisms for Better Outcomes (COMBO)
NCT03689920
Non-Complex Biliary Stones DSC vs ERC
NCT03421340
AXIOS Lumen Apposing Metal Stent for Walled Off Necrosis Drainage IDE Study
NCT03525808
The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia
NCT03551496
Data Collection Atrial Fibrillation Exploratory Study
NCT03647085
Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy
NCT03593681
Minimally Invasive Prostatic Vapor Ablation for the Treatment of BPH in Large Prostates (Rezūm XL)
NCT03605745
Precision Event Monitoring for Patients With Heart Failure Using HeartLogic
NCT03579641
Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology
NCT02702271
A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s)
NCT03350542
An International Pulmonary Embolism Registry Using EKOS
NCT03426124
RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry
NCT03516695
POCS in Liver Transplantation Patients
NCT03205072
Value of Multiple Modalities Using the Spectra WaveWriter Spinal Cord Stimulator System
NCT03251937
Strategic Management to Improve CRT Using Multi-Site Pacing Post Approval Study (Reference # C1918)
NCT03257436
Bronchial Thermoplasty 10+ Year Study
NCT03243292
Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)
NCT03257254
Multiple Cardiac Sensors for the Management of Heart Failure
NCT03237858
Strategic Management to Optimize Response To Cardiac Resynchronization Therapy
NCT03089281
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 16 |
| Phase 3 | 33 |
| Phase 4 | 26 |
Therapeutic Areas
Where Boston Scientific Corporation enrollment is open (later-stage tilt)
22 recruiting of 280 indexed (8% open); 207 completed (74%).
Phase mix: 59 late (III/IV) vs 23 early (I/II) (later-stage heavy).
Top condition: Coronary Artery Disease (8 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Boston Scientific Corporation: open-pipeline peers nationwide
Peers matched on 280 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Boston Scientific Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 280 trials (± recruiting share)
- Regeneron Pharmaceuticals · 280 trials · 22% recruiting
- Alcon Research · 275 trials · 2% recruiting
- Eisai · 287 trials · 2% recruiting
- SWOG Cancer Research Network · 270 trials · 10% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 8% recruiting · 305 trials
- Novo Nordisk A/S · 8% recruiting · 431 trials
- Hoffmann-La Roche · 8% recruiting · 909 trials
- United Therapeutics · 8% recruiting · 63 trials
Related
What to do with this Boston Scientific Corporation page
280 registered trials is a research-attention snapshot, not an endorsement of Boston Scientific Corporation or any single study.
- 22 of Boston Scientific Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Coronary Artery Disease is the condition Boston Scientific Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Coronary Artery Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Boston Scientific Corporation pipeline card: 280 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.